Developing vaccines and antibodies using machine learning
Machine learning-enabled design of prototype pathogen vaccines and antibodies
['FUNDING_OTHER'] · UNIVERSITY OF WASHINGTON · NIH-10861405
This study is working on new vaccines and treatments to help protect people from certain viruses, using advanced technology and teamwork among researchers, so that we can be better prepared for future outbreaks.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF WASHINGTON (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-10861405 on ClinicalTrials.gov |
What this research studies
This research focuses on creating innovative vaccines and antibodies to combat emerging viral pathogens, specifically bunyaviruses and paramyxoviruses. By leveraging machine learning and computational protein design, the team aims to develop effective vaccine prototypes and biologics. The project involves collaboration among five research institutions, utilizing advanced techniques in structural biology and mRNA vaccine technology. Patients may benefit from the development of vaccines that are tailored to effectively target these viruses, enhancing pandemic preparedness.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit from this research include individuals at risk of infection from bunyaviruses and paramyxoviruses, particularly during outbreaks.
Not a fit: Patients who are not at risk for these specific viral infections may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of effective vaccines that protect against serious viral infections.
How similar studies have performed: Previous research has shown success in using computational methods for vaccine design, indicating a promising approach for this novel project.
Where this research is happening
SEATTLE, UNITED STATES
- UNIVERSITY OF WASHINGTON — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KING, NEIL — UNIVERSITY OF WASHINGTON
- Study coordinator: KING, NEIL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.